TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7419830
Drug: Lodoxamide tromethamine
Normalized name: Lodoxamide Tromethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodoxamide tromethamine (0.1 mg)
Study: 7419830
Drug: Lodoxamide tromethamine
Normalized name: Lodoxamide Tromethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodoxamide tromethamine (1.0 mg)
Study: 18806833
Drug: G‐CSF+EPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF+EPO
Study: 15090958
Drug: Albumin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin (25 g of a 25% solution every 8 hrs for a total of nine doses)
Study: 15090958
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline administered in identical fashion and volume)
Study: 15090958
Drug: Albumin treatment
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin treatment group
Study: 7531868
Drug: Bisacodyl suppositories
Normalized name: Bisacodyl Suppositories
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bisacodyl suppositories
Study: 27490086
Drug: Diabetes-specific preparation
Normalized name: Pacific oyster preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes-specific preparation protocol (DSP)
Study: 27490086
Drug: Conventional bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional bowel preparation protocol (CBP)
Study: 24796059
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (sword-like needle + chiropractic spinal manipulation)
Study: 20526718
Drug: Intravenous amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amoxicillin plus clavulanic acid 1 g every 8 h followed by oral antibiotic after improvement and discharge the next day.
Study: 20526718
Drug: Intravenous amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic at discharge.
Study: 19127910
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus medication (routine western medicine)
Study: 19127910
Drug: Medication (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (routine western medicine)
Study: 16721316
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course of family-based therapy (FBT)
Study: 16721316
Drug: Long course
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long course of family-based therapy (FBT)
Study: 1459173
Drug: n‐3 polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 polyunsaturated fatty acids (n‐3 PUFA) supplementation (3.6 g, 12 weeks)
Study: 1459173
Drug: Placebo (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (six capsules with fat composition as the average Danish diet)
Study: 31400177
Drug: Qualitative research
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qualitative research alongside RCTs focusing on illicit drug use
Study: 24951468
Drug: Health-related quality
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health-related quality of life scores between children who received intravenous immunoglobulin and those who were carefully observed
Study: 22150819
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly supervision
Study: 22150819
Drug: Daily supervision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supervision
Study: 17268413
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (8 g/day)
Study: 17268413
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil (11 g/day linoleic acid)
Study: 15703464
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg + acetylsalicylic acid (ASA) 75 mg daily
Study: 15703464
Drug: ASA 75
Normalized name: ASA 75 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 75 mg/day
Study: 15703464
Drug: Extended-release dipyridamole
Normalized name: ASPIRIN 25 mg / DIPYRIDAMOLE 200 mg ORAL CAPSULE, EXTENDED RELEASE [ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release dipyridamole 200 mg/low‐dose ASA 25 mg twice daily
Study: 12075263
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (MED(TMR) and MED(PTMR))
Study: 2539838
Drug: Supplements containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplements containing DHA
Study: 18116
Drug: Oral bucolome
Normalized name: CHICORY LEAF 15.4 g in 100 g ORAL LIQUID [BULOME S]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bucolome (30 mg/kg per day for 5 days)
Study: 18116
Drug: Oral bucolome
Normalized name: CHICORY LEAF 15.4 g in 100 g ORAL LIQUID [BULOME S]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bucolome
Study: 31112406
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of milk protein concentrate (MPC80) with 1.5 g of free leucine (15G+LEU)
Study: 31112406
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of milk protein concentrate (MPC80) without leucine (15G)
Study: 19377494
Drug: Pharmacological therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapies
Study: 18007083
Drug: Traditional tidal
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional tidal volume ventilation (10 mL/kg)
Study: 14670310
Drug: Adult-type dTpa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult-type dTpa booster vaccine (Boostrix)
Study: 2680678
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release salbutamol 8 mg twice daily
Study: 2680678
Drug: Aminophylline 525
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 525 or 700 mg twice daily
Study: 31201653
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behavioral therapy (bCBT) with physical health module
Study: 20733446
Drug: Daily text-message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text-message reminders
Study: 1955620
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 30% calories from fat, 300 mg cholesterol/day
Study: 1955620
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 26% calories from fat, 200 mg cholesterol/day
Study: 1955620
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 22% calories from fat, 100 mg cholesterol/day
Study: 1955620
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 18% calories from fat, 100 mg cholesterol/day
Study: 30127596
Drug: Milnacipran 100
Normalized name: milnacipran 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran 100 mg
Study: 24596459
Drug: IND +
Normalized name: up4 PROBIOTICS Mind + Body 2 Billion CFU Gummies (Very Berry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND + GLY (indacaterol 150 μg and glycopyrronium 50 μg daily)
Study: 24596459
Drug: IND +
Normalized name: up4 PROBIOTICS Mind + Body 2 Billion CFU Gummies (Very Berry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND + PBO (indacaterol 150 μg daily and placebo)
Study: 18066133
Drug: NG440 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG440 (a combination of rho iso-alpha acids from hops, rosemary, and oleanolic acid)
Study: 10210394
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg tolterodine
Study: 10210394
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg tolterodine
Study: 7790604
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at 18 ppm
Study: 7790604
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of prostacyclin (PGI2) at 4 ng.kg-1.min-1
Study: 22368874
Drug: Reduning injection
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduning injection plus antibiotics and basic therapy
Study: 19650964
Drug: Nutrition education
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition education intervention in kindergartens (monthly activities for children and parents)
Study: 31925809
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (STA trial)
Study: 20304051
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (4000 IU vitamin D3 daily for 6 months)
Study: 11828240
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g NH(4)Cl acute administration
Study: 7751874
Drug: 5-FU plus
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU plus IFN (10 MU subcutaneously three times weekly)
Study: 7751874
Drug: 5-FU alone
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU alone (750 mg/m2/d by continuous infusion for 5 consecutive days followed by weekly bolus 5-FU 750 mg/m2)
Study: 2281582
Drug: 75 ml
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 ml of ioversol (Optiray-320)
Study: 2281582
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of diatrizoate (Renografin-60)
Study: 382393
Drug: Meptazinol 100
Normalized name: meptazinol 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol 100 mg intramuscularly
Study: 382393
Drug: Omnopon 20
Normalized name: Omnopon 20 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omnopon 20 mg intramuscularly
Study: 31723037
Drug: Heat-stable microparticle
Normalized name: (9-L-TYROSINE)HEAT-STABLE ENTEROTOXIN (ESCHERICHIA COLI)-(6-19)-PEPTIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-stable microparticle platform for oral micronutrient delivery (BMC)
Study: 31723037
Drug: Initial human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial human study of iron bioavailability from microparticles
Study: 29429177
Drug: Planned neck
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Planned neck dissection (PND) + concurrent chemoradiotherapy (CCRT)
Study: 23852695
Drug: Tanezumab 10
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 10 mg + Diclofenac Sustained Release (DSR) 75 mg
Study: 23852695
Drug: Tanezumab 5
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 5 mg + Diclofenac Sustained Release (DSR) 75 mg
Study: 23852695
Drug: Tanezumab 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 2.5 mg + Diclofenac Sustained Release (DSR) 75 mg
Study: 23852695
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Diclofenac Sustained Release (DSR) 75 mg
Study: 20137768
Drug: Test tablets
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test tablets (Gen‐Nifedipine extended release)
Study: 20137768
Drug: Reference tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference tablets (Adalat XL)
Study: 30218764
Drug: Prospective screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospective screening program for C. difficile prior to cystectomy with prophylactic treatment using metronidazole.
Study: 28179024
Drug: 4-monthly albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-monthly albendazole treatment
Study: 28179024
Drug: Single annual
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single annual albendazole treatment
Study: 22303641
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg kg(‐1) morphine
Study: 9645635
Drug: 0.75% topical
Normalized name: Nydamax 0.75% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% topical metronidazole gel
Study: 9645635
Drug: topical metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical metronidazole vehicle gel (placebo)
Study: 2841172
Drug: Trimethoprim-polymyxin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-polymyxin B sulphate ophthalmic ointment (5 mg/g and 10,000 units/g)
Study: 2841172
Drug: Chloramphenicol ophthalmic
Normalized name: chloramphenicol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol ophthalmic ointment (1%)
Study: 29660670
Drug: Tilt group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilt group (passive tilting added to standardized rehabilitation therapy)
Study: 29660670
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standardized rehabilitation therapy alone)
Study: 23529918
Drug: Aerobic Exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic Exercise Training (AET) + Antihypertensive Drugs (ADs)
Study: 23529918
Drug: Antihypertensive Drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive Drugs (ADs) alone
Study: 18326592
Drug: TFAs from
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFAs from natural sources (11-12 g/d, approximately 5% of daily energy)
Study: 16566972
Drug: Antibiotics and
Normalized name: Antibiotics and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics and prostatic massage (group 1: n = 17)
Study: 16566972
Drug: Antibiotics alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics alone (group 2: n = 20)
Study: 16566972
Drug: Antibiotics and
Normalized name: Antibiotics and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics and prostatic massage (group 3: n = 25)
Study: 16566972
Drug: Antibiotics alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics alone (group 4: n = 19)
Study: 11902250
Drug: Continuous venovenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous venovenous hemofiltration (CVVH) at 2 L/hr for 48 hrs
Study: 1693316
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with ifosfamide, cisplatin, and bleomycin (BIP) prior to radiotherapy
Study: 6749634
Drug: Choleitholytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choleitholytic therapy
Study: 30513347
Drug: Single-site bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-site bolus NGF injection (5 µg)
Study: 30513347
Drug: Spatially distributed
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spatially distributed low-dose NGF injections (1 µg, 4 cm distance)
Study: 30048048
Drug: Moderately rough
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately rough implant (Sa: 1.3 μm)
Study: 30048048
Drug: Hybrid surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid surface implant (moderately rough implant body [Sa: 1.3 μm] and minimally rough implant neck [Sa: 0.9 μm])
Study: 26205305
Drug: Process-based cognitive
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Process-based cognitive training (pb-CT) combined with reminiscence therapy (RT) for 3 months
Study: 24254057
Drug: Barley oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barley oil supplements
Study: 24254057
Drug: Palm oil
Normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palm oil supplements
Study: 16286543
Drug: Topiramate (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (target dose, 400 mg/d in adults)
Study: 10210384
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg furosemide on second visit
Study: 10210384
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg furosemide on first visit
Study: 350497
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g salsalate per day
Study: 350497
Drug: 3.6 g
Normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g soluble aspirin per day
Study: 29463421
Drug: HZ/su vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZ/su vaccine
Study: 23850262
Drug: ApoC-III in
Approvals — FDA: no, EMA: no, PMDA: no
Description: ApoC-III in VLDL (heparin-manganese precipitate)
Study: 23850262
Drug: ApoC-III in
Approvals — FDA: no, EMA: no, PMDA: no
Description: ApoC-III in HDL (heparin-manganese supernatant)
Study: 17241101
Drug: Supratherapeutic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supratherapeutic doses of salbutamol (800-1200μg)
Study: 17241101
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of salbutamol
Study: 15570242
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH, 450 IU/kg/24 hr)
Study: 15570242
Drug: Subcutaneous dalteparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dalteparin, 100 IU/kg given twice at a 12-hr interval
Study: 15570242
Drug: Subcutaneous dalteparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dalteparin, 200 IU/kg given once
Study: 15570242
Drug: Saline-solution infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline-solution infusion
Study: 10228904
Drug: CA 125
Normalized name: ACA 125
DrugBank: ACA 125 (DB05489)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA 125 screening with a cutoff value of 30 U/mL
Study: 7611754
Drug: Intraarterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarterial infusion of Epi‐adriamycin 30‐40 mg/body and CDDP 100 mg/body via reservoir every two weeks post‐operatively (group R)
Study: 7611754
Drug: One-shot infusion
Normalized name: ChoreMate One-Shot
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-shot infusion of Epi‐adriamycin or adriamycin (group O)
Study: 30753368
Drug: Human rotavirus
Normalized name: Live attenuated human Rotavirus RIX4414 strain Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human rotavirus vaccine (HRV)
Study: 22393898
Drug: Bilastine 100
Normalized name: bilastine
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Bilastine 100 mg
Study: 21642470
Drug: Bilastine 20
Normalized name: Bilastine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilastine 20 mg with Ketoconazole 400 mg
Study: 19473072
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program with low-level laser therapy (LLLT); 904-nm Ga-As laser in continuous mode, power density 130 mW/cm², dose 0.585 J/point.
Study: 19473072
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program with polarized polychromatic non-coherent light (Bioptron 2); administered perpendicularly to the lateral epicondyle at three points for 6 min at each position.
Study: 7760093
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg etomidate
Study: 11136139
Drug: 0.05‐0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05‐0.1 mg/kg midazolam (control group)
Study: 9633671
Drug: Tryptophan depletion
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan depletion (tryptophan-free amino acid beverage plus amino acid capsules)
Study: 7020738
Drug: Busulphan treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulphan treatment
Study: 7935995
Drug: Remission after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remission after busulphan treatment
Study: 3346570
Drug: Q fever
Normalized name: Q fever
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q fever vaccine
Study: 26993648
Drug: Large volumes
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large volumes of thin liquids (90 ml)
Study: 24229481
Drug: Manualized psychodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manualized psychodynamic therapy (PDT)
Study: 24229481
Drug: Waiting list/treatment-as-usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list/treatment-as-usual (WL/TAU)
Study: 23537708
Drug: Etoposide in
Normalized name: etoposide Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide in combination with low-dose CAG (E-CAG)
Study: 18188694
Drug: Lapatinib 1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1,250 mg/day plus capecitabine 2,000 mg/m2 days 1-14 of a 21-day cycle
Study: 18188694
Drug: Capecitabine 2,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 2,500 mg/m2 on the same schedule
Study: 16896785
Drug: Amlodipine-atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine-atorvastatin (10 mg + 20 mg)
Study: 10992375
Drug: Indwelling catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indwelling catheter replacement before antimicrobial therapy
Study: 10992375
Drug: No catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: No catheter replacement before antimicrobial therapy